What are ORMALVI (Dichlorphenamide) Tablets?

With ORMALVI, you may be able to offer your patients Primary Periodic Paralysis treatment with confidence.

ORMALVI is a proven treatment for Primary Periodic Paralysis. It is indicated for the treatment of hyperkalemic periodic paralysis, hypokalemic periodic paralysis and related variants.1

Dichlorphenamide is well tolerated in patients with Primary Periodic Paralysis and is the only medication approved by the FDA for the treatment of PPP.2 It can help patients feel more confident by reducing the frequency and severity of attacks.3

Dichlorphenamide is a carbonic anhydrase inhibitor, however the precise mechanism by which dichlorphenamide exerts its therapeutic effects in patients with Primary Periodic Paralysis is unknown.1


The recommended starting dose of ORMALVI is 50 mg twice daily. This dosage may be increased or decreased at weekly intervals, based on individual response. The minimum recommended dose is 50 mg daily and the maximum recommended dose is 200 mg daily. The response to ORMALVI should be evaluated after two months of therapy.1

Baseline and periodic measurements of serum potassium and serum bicarbonate during ORMALVI treatment is recommended.1

Find out more about Primary Periodic ParalysisEnroll your patients


  1. ORMALVI (dichlorphenamide). Prescribing Information. Cycle Pharmaceuticals Ltd.
  2. Greig. S. L., (2016). Drugs. Dichlorphenamide: A Review in Primary Periodic Paralyses. 76 (4): 501-507. Available at: https://doi.org/10.1007/s40265-016-0559-2 [Accessed 1 Nov. 2023].
  3. Statland, J., et al (2017). Review of the Diagnosis and Treatment of Periodic Paralysis. Muscle & Nerve, [online] 57(4), pp.522–530. Available at: https://doi.org/10.1002/mus.26009 [Accessed 1 Nov. 2023].